Known targets — ChEMBL curated mechanism
ADRB1ADRB2SCN10ASCN11ASCN1ASCN2ASCN3ASCN4ASCN5ASCN7ASCN8ASCN9A
The experimentally established mechanism targets of Propafenone. The predicted profile below is derived independently by chemical similarity — agreement is a validation signal, a miss is honest.
Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ADRB2 known ✓ | P07550 | 1/20 | 1.00 |
| ▸ | ADRB1 known ✓ | P08588 | 1/20 | 1.00 |
| ▸ | SCN5A known ✓ | Q14524 | 1/20 | 1.00 |
| ▸ | ABCB1 | P08183 | 17/20 | 1.00 |
| ▸ | LMNA | P02545 | 2/20 | 1.00 |
| ▸ | CYP1A2 | P05177 | 2/20 | 1.00 |
| ▸ | CYP2D6 | P10635 | 2/20 | 1.00 |
| ▸ | CYP3A4 | P08684 | 2/20 | 1.00 |
| ▸ | KCNH2 | Q12809 | 2/20 | 1.00 |
| ▸ | TSHR | P16473 | 2/20 | 1.00 |
| ▸ | KCNK3 | O14649 | 1/20 | 1.00 |
| ▸ | SLC22A1 | O15245 | 1/20 | 1.00 |
| ▸ | ABCC9 | O60706 | 1/20 | 1.00 |
| ▸ | KCNK2 | O95069 | 1/20 | 1.00 |
| ▸ | ABCB11 | O95342 | 1/20 | 1.00 |
| ▸ | ADRB3 | P13945 | 1/20 | 1.00 |
| ▸ | ADRA2C | P18825 | 1/20 | 1.00 |
| ▸ | SLC6A2 | P23975 | 1/20 | 1.00 |
| ▸ | HTR2A | P28223 | 1/20 | 1.00 |
| ▸ | HTR2C | P28335 | 1/20 | 1.00 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Propafenone SCHEMBL30416841 | 1.00 | ABCB1 (1.00) | ABCB1LMNACYP1A2CYP2D6CYP3A4 | |
| Propafenone SCHEMBL41413 | 1.00 | ABCB1 (1.00) | ABCB1LMNACYP1A2CYP2D6CYP3A4 | |
| Propafenone SCHEMBL27865 | 1.00 | ABCB1 (1.00) | ABCB1LMNACYP1A2CYP2D6CYP3A4 | |
| Propafenone SCHEMBL5529275 | 0.99 | MEN1 (1.00) | ABCB1LMNACYP1A2CYP2D6CYP3A4 | |
| Propafenone SCHEMBL29384899 | 0.99 | MEN1 (1.00) | ABCB1LMNACYP1A2CYP2D6CYP3A4 | |
| Propafenone SCHEMBL41412 | 0.99 | MEN1 (1.00) | ABCB1LMNACYP1A2CYP2D6CYP3A4 | |
| Propafenone SCHEMBL1651012 | 0.98 | ABCB1 (0.96) | ABCB1LMNACYP1A2CYP2D6CYP3A4 | |
| SCHEMBL29419081 | 0.94 | ABCB1 (0.88) | ABCB1LMNACYP1A2CYP2D6CYP3A4 | |
| Propafenone SCHEMBL15539494 | 0.91 | ABCB1 (0.83) | ABCB1LMNACYP1A2CYP2D6CYP3A4 | |
| Propafenone SCHEMBL924632 | 0.89 | ABCB1 (0.79) | ABCB1LMNACYP1A2CYP2D6CYP3A4 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 168 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-3863708-B1 | MIXED IONIC CONDUCTORS AND CORRESPONDING DEVICES, SYSTEMS AND METHODS OF MAKING | BATTELLE MEMORIAL INSTITUTE (US) | 2024-09-11 | — | — | EP | claimed |
| EP-4057999-B1 | PROCESS FOR PREPARING NANO- OR MICROPARTICLES COMPRISING A CARRIER-POLYMER AND ONE OR MORE BIOLOGICALLY ACTIVE INGREDIENTS | EVONIK OPERATIONS GMBH (DE) | 2023-12-13 | — | — | EP | claimed |
| EP-3485876-B1 | ORAL PHARMACEUTICAL COMPOSITION AND METHOD FOR PRODUCING PARTICULATE FORMULATION COMPRISING COMPOSITION | SUNSHO PHARMACEUTICAL CO LTD (JP) | 2023-11-22 | — | — | EP | claimed |
| US-11819576-B2 | Process for preparing nano-or microparticles comprising a carrier-polymer and one or more biologically active ingredients | EVONIK OPERATIONS GMBH (DE) | 2023-11-21 | — | — | US | claimed |
| US-20230147853-A1 | PROCESS FOR PREPARING NANO- OR MICROPARTICLES COMPRISING A CARRIER-POLYMER AND ONE OR MORE BIOLOGICALLY ACTIVE INGREDIENTS | EVONIK OPERATIONS GMBH (DE) | 2023-05-11 | — | — | US | claimed |
| EP-3891505-B1 | A METHOD FOR MEASURING A CONCENTRATION OF A BIOMARKER/ANALYTE IN BLOOD FROM MAMMALS | REDHOTDIAGNOSTICS AB (SE) | 2022-11-30 | — | — | EP | claimed |
| EP-3693466-B1 | METHOD AND SYSTEM FOR PREPARING RECOMBINANT ADENO-ASSOCIATED VIRUS, AND RECOMBINANT BACMID | INNOVATION ACADEMY FOR PRECISION MEASUREMENT SCIENCE AND TECH CHINESE ACADEMY OF SCIENCES (CN) | 2022-10-19 | — | — | EP | claimed |
| EP-2991588-B1 | PROSTHETIC TISSUE VALVES | CORMATRIX CARDIOVASCULAR INC (US) | 2022-10-12 | — | — | EP | claimed |
| EP-4057999-A1 | PROCESS FOR PREPARING NANO- OR MICROPARTICLES COMPRISING A CARRIER-POLYMER AND ONE OR MORE BIOLOGICALLY ACTIVE INGREDIENTS | Evonik Operations GmbH (DE) | 2022-09-21 | — | — | EP | claimed |
| CN-115024314-A | Agrochemical composition | 巴特尔英国有限公司 | 2022-09-09 | — | — | CN | claimed |
| CN-113316389-B | Agrochemical composition | 巴特尔英国有限公司 | 2022-07-22 | — | — | CN | claimed |
| EP-1931320-B1 | MICROPARTICLES WITH MODIFIED RELEASE OF AT LEAST ONE ACTIVE PRINCIPLE AND ORAL DOSAGE FORM COMPRISING THE SAME | FLAMEL IRELAND LTD (IE) | 2022-06-15 | — | — | EP | claimed |
| EP-3753966-B1 | AMPHIPHILIC BLOCK COPOLYMER, PREPARATION METHOD THEREOF AND NANOMICELLE DRUG-LOADING SYSTEM | SHANGHAI BEST LINK BIOSCIENCE LLC (CN) | 2022-05-25 | — | — | EP | claimed |
| US-10888552-B2 | Treatment of disorders of sexual arousal with local application of agents that increase membrane excitability | Rothman, Steven (US) | 2021-01-12 | — | — | US | claimed |
| US-20190192493-A1 | TREATMENT OF DISORDERS OF SEXUAL AROUSAL WITH LOCAL APPLICATION OF AGENTS THAT INCREASE MEMBRANE EXCITABILITY | ROTHMAN STEVEN (US) | 2019-06-27 | — | — | US | claimed |
| US-9119841-B2 | Compositions and methods for preventing cardiac arrhythmia | CORMATRIX CARDIOVASCULAR, INC. (US) | 2015-09-01 | — | — | US | claimed |
| US-20150164959-A1 | Compositions and Methods for Preventing Cardiac Arrhythmia | CORVIVO CARDIOVASCULAR, INC. | 2015-06-18 | — | — | US | claimed |
| EP-4656189-A1 | COMPOUND AND USE THEREOF | Benethera (Shaoxing) Biotechnology Co., Ltd. (CN) | 2025-12-03 | — | — | EP | disclosed |
| US-8088918-B2 | Noncardiotoxic pharmaceutical compounds | WILLIAMSBURG HOLDINGS LLC (US) | 2012-01-03 | — | — | US | disclosed |
| CN-101928356-A | Bis-[6-oxa-(2-carboxylbenzenesulfonyl-butanedioic acid 1,4 monoester-4)-beta-cyclodextrin, preparation method and application thereof | UNIV SOUTH CENTRAL NATIONALITI | 2010-12-29 | — | — | CN | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20190192493-A1 | TREATMENT OF DISORDERS OF SEXUAL AROUSAL WITH LOCAL APPLICATION OF AGENTS THAT INCREASE MEMBRANE EXCITABILITY | GABRE, SLC18A2, SLC18A1 | ADRB2 474/4885ADRB1 1066/4885SCN5A 1614/4885 |
| US-10888552-B2 | Treatment of disorders of sexual arousal with local application of agents that increase membrane excitability | GABRE, SLC18A2, SLC18A1 | ADRB2 474/4885ADRB1 1066/4885SCN5A 1614/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.